CompletedPhase 3NCT03643965
Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Calliditas Therapeutics AB
- Principal Investigator
- Krassimir Mitchev, MD, M.DCalliditas AB
- Intervention
- Nefecon(drug)
- Enrollment
- 365 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2023
Study locations (30)
- University of Alabama at Birmingham, 1720 2nd Ave South, Birmingham, Alabama, United States
- Univ of Arizona, 1501 N Campbell Ave, Tucson, Arizona, United States
- Stanford University Medical Center, 777 Welch Rd, Palo Alto, California, United States
- Los Angeles Biomedical Research Institute at HUMC, 1124 W. Carson Street, Torrance, California, United States
- University of Colorado Health Science Center, 1200 East 19th Av., Aurora, Colorado, United States
- Western Nephrology and Metabolic Bone Disease, PC-Westerminster, 8410 Decatur St., Westminster, Colorado, United States
- Yale University School of Medicine, 330 Cedar Street, New Haven, Connecticut, United States
- Washington Nephrology Associates-Washington DC, 730 24th Street NW, Washington D.C., District of Columbia, United States
- University of Florida-Gainesville, Gainesville, Florida, United States
- Omega Research Maitland, 7912 Forest City Rd., Orlando, Florida, United States
- Omega Research Maitland, Orlando, Florida, United States
- Northwestern University the Feinberg School of Medicine, 633 North St. Clair, Chicago, Illinois, United States
- Northshore University Health System, 2650 Ridge Av., Evanston, Illinois, United States
- University of Kentucky Medical Center, 800 Rose St, Pavillion H 3rd floor, Lexington, Kentucky, United States
- University of Louisville-Nephrology, Louisville, Kentucky, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03643965 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital